These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 17215493)
1. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Dombi E; Solomon J; Gillespie AJ; Fox E; Balis FM; Patronas N; Korf BR; Babovic-Vuksanovic D; Packer RJ; Belasco J; Goldman S; Jakacki R; Kieran M; Steinberg SM; Widemann BC Neurology; 2007 Feb; 68(9):643-7. PubMed ID: 17215493 [TBL] [Abstract][Full Text] [Related]
2. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. Nguyen R; Kluwe L; Fuensterer C; Kentsch M; Friedrich RE; Mautner VF J Pediatr; 2011 Oct; 159(4):652-5.e2. PubMed ID: 21621223 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997 [TBL] [Abstract][Full Text] [Related]
4. Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. Cai W; Steinberg SM; Bredella MA; Basinsky G; Somarouthu B; Plotkin SR; Solomon J; Widemann BC; Harris GJ; Dombi E Acad Radiol; 2018 Feb; 25(2):144-152. PubMed ID: 29097016 [TBL] [Abstract][Full Text] [Related]
5. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Solomon J; Warren K; Dombi E; Patronas N; Widemann B Comput Med Imaging Graph; 2004 Jul; 28(5):257-65. PubMed ID: 15249071 [TBL] [Abstract][Full Text] [Related]
6. Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice. Pratt L; Helfer D; Weizman L; Shofty B; Constantini S; Joskowicz L; Ben Bashat D; Ben-Sira L Acta Neurochir (Wien); 2015 May; 157(5):855-61. PubMed ID: 25772343 [TBL] [Abstract][Full Text] [Related]
7. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394 [TBL] [Abstract][Full Text] [Related]
9. Superficial neurofibroma: a lesion with unique MRI characteristics in patients with neurofibromatosis type 1. Lim R; Jaramillo D; Poussaint TY; Chang Y; Korf B AJR Am J Roentgenol; 2005 Mar; 184(3):962-8. PubMed ID: 15728625 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379 [TBL] [Abstract][Full Text] [Related]